ClinicalTrials.gg
Not yet recruitingNCT07938944Updated Nov 16, 2026

Topical Corticosteroid Phobia and Personalized Behavioral Intervention (BERANI) Among Parents of Children With Atopic Dermatitis: A Multicenter RCT in Indonesia

An interventional study of BERANI in Topical Corticosteroid Phobia, sponsored by Gadjah Mada University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Gadjah Mada University · Not applicable, Interventional, and Supportive care

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to understand the prevalence of topical corticosteroid phobia and to identify if personalized behavior intervention method can reduce the score of topical corticosteroid phobia among parents or caregivers of children with atopic dermatitis. The aims of the study are:

  • to describe the prevalence of topical corticosteroid phobia in Indonesia
  • to identify risk factor of topical corticosteroid phobia among parents of children with atopic dermatitis
  • to evaluate if the intervention of BERANI method will reduce the score of topical corticosteroid phobia
  • to assess the impact of intervention to the compliance and clinical outcome

Researchers will compare BERANI method to a standard care to see if BERANI method will reduce the score of topical corticosteroid phobia.

Participants will:

  • fill a questionnaire and undergo physical examination for assessing the severity of atopic dermatitis
  • get an audiovisual education or standard care education during the first visit based on randomization
  • return in 14 days to fill a questionnaire and undergo physical examination.
02

Conditions studied

  • Topical Corticosteroid Phobia

Browse trials for

03

In context

Phobic Disorders

85 studies on the registry are indexed under Phobic Disorders; 16 are open to participants now.

This study's planned enrollment of 90 is above the median of 66 across 70 interventional studies indexed under Phobic Disorders.

Browse Phobic Disorders studies →

Lead sponsor

Gadjah Mada University is the lead sponsor of 64 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents or primary caregivers of pediatric patients (aged ≤18 years) with atopic dermatitis.
  • Patients currently receiving or scheduled to receive topical therapy.
  • Willingness to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Cognitive or psychiatric impairments that may hinder the educational process.
  • Lack of access to WhatsApp for follow-up communication.
  • Participation in a similar study within the past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    BERANI

    BERANI is a personalized behavior intervention to manage the topical corticosteroid phobia among parents of children with atopic dermatitis. BERANI stands for: B (Brief screening); E (Express concerns); R (Reassure \& rectify); A (Audiovisual education); N (Navigate understanding); I (Intensify follow-up)

    Behavioral: BERANI

  • No intervention
    Standard Care

    Patient will receive a standard education related to topical corticosteroid use for atopic dermatitis

Interventions

  • BehavioralBERANI

    BERANI is a personalized behavior intervention to manage the topical corticosteroid phobia among parents of children with atopic dermatitis. BERANI stands for: 1. B (Brief screening) Screening using TOPICOP questionnaire to identify the scale of topical corticosteroid phobia 2. E (Express concerns) Parents or caregivers are given chance to express their concern to apply topical corticosteroid 3. R (Reassure \& rectify) Physicians respond emphatically to their concerns and explain the safety and use of corticosteroid 4. A (Audiovisual education) One or more audiovisual educational will be delivered (2-3 minutes), with content tailored to the specific topics of concern 5. N (Navigate understanding) Parents will be asked to reiterate their understanding using the teach-back method and develop a simple plan for implementing the therapy 6. I (Intensify follow-up) WhatsApp-based reinforcement through educational materials, videos, and therapy-use reminders during the 2-week follow-up.

06

What researchers measure

Primary outcomes

  1. Topical Corticosteroid Phobia Score

    The topical corticosteroid phobia score will be assessed using TOPICOP instrument in Bahasa Indonesia.

    Time frame: From enrollment to the end of intervention at 2 weeks

Secondary outcomes

  1. Compliance of Topical Corticosteroid Use for Atopic Dermatitis

    Compliance of topical corticosteroid use will be assessed using 12-item Medication Adherence Scale (MAS) in Bahasa Indonesia.

    Time frame: From enrollment to the end of intervention at 2 weeks

  2. Disease Severity of Atopic Dermatitis

    The disease severity of atopic dermatitis will be assessed using EASI score.

    Time frame: From enrollment to the end of intervention at 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kelompok Studi Dermatologi Anak Indonesia. Data morbiditas Kelompok Studi Dermatologi Anak Indonesia 2024.
  • Kenley H, Gunawan S. Gambaran corticophobia pasien psoriasis di Indonesia: studi berbasis TOPICOP. Damianus J Med. 2024;23(3):206-215.
  • Lee JY, Her Y, Kim CW, Kim SS. Topical Corticosteroid Phobia among Parents of Children with Atopic Eczema in Korea. Ann Dermatol. 2015 Oct;27(5):499-506. doi: 10.5021/ad.2015.27.5.499. Epub 2015 Oct 2. PubMed 26512163 ↗
  • Albogami MF, AlJomaie MS, Almarri SS, Al-Malki S, Tamur S, Aljaid M, Khayat A, Alzahrani A. Topical Corticosteroid Phobia Among Parents of Children with Atopic Dermatitis (Eczema)- A Cross-Sectional Study. Patient Prefer Adherence. 2023 Nov 2;17:2761-2772. doi: 10.2147/PPA.S431719. eCollection 2023. PubMed 37936715 ↗
  • Contento M, Cline A, Russo M. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. Am J Clin Dermatol. 2021 Nov;22(6):837-851. doi: 10.1007/s40257-021-00623-6. Epub 2021 Jul 21. PubMed 34287768 ↗
  • Starbek Zorko M, Bukovec V, Fantulin T. Topical Corticosteroid Phobia in Childhood Atopic Dermatitis: A Study Using the TOPICOP Score. Dermatol Res Pract. 2026 Mar 6;2026:7996688. doi: 10.1155/drp/7996688. eCollection 2026. PubMed 41797838 ↗
  • Davis DMR, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2026 Jul;95(1):121.e1-121.e26. doi: 10.1016/j.jaad.2026.02.113. Epub 2026 Apr 7. PubMed 41949508 ↗
  • Ueno H, Yamazaki Y, Yonekura Y, Park MJ, Ishikawa H, Kiuchi T. Reliability and validity of a 12-item medication adherence scale for patients with chronic disease in Japan. BMC Health Serv Res. 2018 Jul 31;18(1):592. doi: 10.1186/s12913-018-3380-7. PubMed 30064422 ↗
  • Promthes T, Techasatian L, Salee-Or S, Uppala R, Sitthikarnkha P, Saengnipanthkul S, Sirikarn P, Kosalaraksa P. Topical corticosteroid phobia among caregivers: a study in atopic and nonatopic dermatitis children by using the TOPICOP score. Skin Health Dis. 2025 Jul 25;5(5):372-377. doi: 10.1093/skinhd/vzaf056. eCollection 2025 Oct. PubMed 41035840 ↗
  • Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. J Allergy Clin Immunol. 2025 Apr;155(4):1124-1132. doi: 10.1016/j.jaci.2025.01.013. Epub 2025 Jan 22. PubMed 39855361 ↗
  • Lee DG, Gui XY, Mukovozov I, Fleming P, Lynde C. Sleep Disturbances in Children With Atopic Dermatitis: A Scoping Review. J Cutan Med Surg. 2023 Mar-Apr;27(2):157-164. doi: 10.1177/12034754231159337. Epub 2023 Mar 7. PubMed 36880965 ↗
  • Moret L, Anthoine E, Aubert-Wastiaux H, Le Rhun A, Leux C, Mazereeuw-Hautier J, Stalder JF, Barbarot S. TOPICOP(c): a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013 Oct 16;8(10):e76493. doi: 10.1371/journal.pone.0076493. eCollection 2013. PubMed 24146878 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 28 interventional studies with no phase under Phobic Disorders, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 44. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938944
Lead sponsor
Gadjah Mada University
Collaborators
Indonesian Society of Dermatology and Venereology
Responsible party
Tuntas Rayinda (MD, PhD, Gadjah Mada University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Tuntas Rayinda, MD, PhD
Contact
tuntas.rayinda@ugm.ac.id
+62 (274) 560700

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion